CLINUVEL PHARMACEUTICALS LTD (Seite 2256)
eröffnet am 24.04.07 13:00:35 von
neuester Beitrag 21.01.25 12:23:49 von
neuester Beitrag 21.01.25 12:23:49 von
Beiträge: 22.612
ID: 1.126.403
ID: 1.126.403
Aufrufe heute: 98
Gesamt: 4.113.073
Gesamt: 4.113.073
Aktive User: 0
ISIN: AU000000CUV3 · WKN: A0JEGY · Symbol: UR9
7,0250
EUR
+0,79 %
+0,0550 EUR
Letzter Kurs 07.02.25 Tradegate

Neuigkeiten
TitelBeiträge |
---|
29.01.25 · wO Chartvergleich |
01.10.24 · globenewswire |
25.06.24 · wO Chartvergleich |
18.06.24 · globenewswire |
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,1900 | +54,55 | |
3,5100 | +25,81 | |
0,5698 | +24,96 | |
0,9000 | +22,43 | |
2,2800 | +20,63 |
Wertpapier | Kurs | Perf. % |
---|---|---|
3,0800 | -35,16 | |
2,5800 | -30,27 | |
1,1600 | -20,55 | |
7,5500 | -34,91 | |
1,0700 | -22,46 |
Beitrag zu dieser Diskussion schreiben
Gab auch wieder einen positiven Bericht von tradecenter.

Hallo,
ein weiterer Schritt in Richtung Registration von CUV1647
.......
Melbourne, Australia July 19th 2007
Clinuvel Pharmaceuticals Ltd (ASX: CUV, Germany-XETRA: UR9) announced today that it has determined the optimal dosage and delivery vehicle for its proprietary photo protective drug CUV1647. Following completion of the most recent pharmacokinetic study in healthy volunteers, Clinuvel has chosen a bioabsorbable*, controlled release** implant with 16 mg loading of CUV1647.
The rate at which the selected implant releases CUV1647 is based on a range of characteristics including its length, diameter, polymer content and implant coating material. Clinuvel selected four implants with differing CUV1647 dosages (10, 12, 16 and 20 mg), from several hundred implant formulations initially evaluated in vitro (laboratory).
Pharmacokinetic trials in healthy Caucasian volunteers at the Centre for Pharmaceutical Research in Adelaide demonstrated that the 16 mg implant was the preferred dosage form. This implant induces photo-protective skin darkening which lasted about 60 days in fair-skinned individuals, i.e. those most in need of protection from UV radiation. This implant provides optimal blood levels of CUV1647 for approximately five days after which the polymer, from which the implant is made, safely dissolves and disappears from the site of injection.
Clinuvel’s CEO, Dr Philippe Wolgen said:
“It has taken 18 months of intense research from our team to arrive at this point in the program. While we continue to focus on the patients affected by UV and light related disorders, the selection of the final dosage form is an important step towards registration of CUV1647.”
.............
mfg opi
ein weiterer Schritt in Richtung Registration von CUV1647
.......
Melbourne, Australia July 19th 2007
Clinuvel Pharmaceuticals Ltd (ASX: CUV, Germany-XETRA: UR9) announced today that it has determined the optimal dosage and delivery vehicle for its proprietary photo protective drug CUV1647. Following completion of the most recent pharmacokinetic study in healthy volunteers, Clinuvel has chosen a bioabsorbable*, controlled release** implant with 16 mg loading of CUV1647.
The rate at which the selected implant releases CUV1647 is based on a range of characteristics including its length, diameter, polymer content and implant coating material. Clinuvel selected four implants with differing CUV1647 dosages (10, 12, 16 and 20 mg), from several hundred implant formulations initially evaluated in vitro (laboratory).
Pharmacokinetic trials in healthy Caucasian volunteers at the Centre for Pharmaceutical Research in Adelaide demonstrated that the 16 mg implant was the preferred dosage form. This implant induces photo-protective skin darkening which lasted about 60 days in fair-skinned individuals, i.e. those most in need of protection from UV radiation. This implant provides optimal blood levels of CUV1647 for approximately five days after which the polymer, from which the implant is made, safely dissolves and disappears from the site of injection.
Clinuvel’s CEO, Dr Philippe Wolgen said:
“It has taken 18 months of intense research from our team to arrive at this point in the program. While we continue to focus on the patients affected by UV and light related disorders, the selection of the final dosage form is an important step towards registration of CUV1647.”
.............
mfg opi
Gute News. Bin mal auf 2008 bzw. 2009 gespannt. Dann soll die Zulassung erfolgen.
http://ept.irmau.com/irm/Company/ShowPage.aspx?CPID=1444
Company Announcement
Dr Aston appointed to Biological Committee of Government IR&D Board
Melbourne, Australia July 10th, 2007 Clinuvel Pharmaceuticals Limited (ASX: CUV, Germany-XETRA:UR9)
is pleased to announce that Dr Roger Aston, Clinuvel’s Executive Chairman has been appointed as a member
of the Biological Committee of the Industry Research and Development Board. Dr Aston was appointed to the
Board by The Hon Ian Macfarlane, Australia’s Minister for Industry, Tourism and Resources.
The Board was established on 1 July 1986, under the Industry Research and Development Act 1986. Its
mission is to increase the economic return from successful technology-based enterprises in Australia by guiding
the Australian Government's investment in the commercialisation of the nation's research and development and
innovation. The Biological Committee assesses Commercial Ready applications, and variations to R&DStart
and BIF grants, and makes recommendations for grant funding involving products, processes or services in the
following industries: health, medical sciences, agriculture, fishing, forestry, environmental, food-processing.
(Source: www.ausindustry.gov.au)
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited (ASX:CUV, XETRA/DAX:UR9, ADR:CUVLY) is an Australian
biopharmaceutical company developing its photo-protective drug CUV1647 as a preventative treatment for a
range of UV-related skin disorders as well as in cancer related treatments.
The five indications are:
Indication Description Clinical Trial Status
Polymorphic Light Eruption
(PLE / PMLE)
Sun poisoning Phase III trials began May 2007
Erythropoietic Protoporphyria (EPP) Absolute sun intolerance Phase III trials began June 2007
Squamous Cell Carcinoma (SCC)
and Actinic Keratosis (AK) in organ
transplant patients
Non-melanoma skin
cancers / precursor
to skin cancers
Phase II trials planned to
begin 2007
Solar Urticaria (SU) Acute anaphylactic
reaction to sun
Phase II trials planned to
begin 2007
Phototoxicity associated with
Photodynamic Therapy (PDT)
Photo-sensitivity associated
with cancer treatment
Phase II trials planned to
begin 2007
Phase I and II human clinical trials using CUV1647 have demonstrated that the drug is well tolerated and no
significant safety concerns have been identified to date.
Following successful conclusion of the development program, Clinuvel will work closely with global regulators to
facilitate marketing approval of CUV1647.
-END
Company Announcement
Dr Aston appointed to Biological Committee of Government IR&D Board
Melbourne, Australia July 10th, 2007 Clinuvel Pharmaceuticals Limited (ASX: CUV, Germany-XETRA:UR9)
is pleased to announce that Dr Roger Aston, Clinuvel’s Executive Chairman has been appointed as a member
of the Biological Committee of the Industry Research and Development Board. Dr Aston was appointed to the
Board by The Hon Ian Macfarlane, Australia’s Minister for Industry, Tourism and Resources.
The Board was established on 1 July 1986, under the Industry Research and Development Act 1986. Its
mission is to increase the economic return from successful technology-based enterprises in Australia by guiding
the Australian Government's investment in the commercialisation of the nation's research and development and
innovation. The Biological Committee assesses Commercial Ready applications, and variations to R&DStart
and BIF grants, and makes recommendations for grant funding involving products, processes or services in the
following industries: health, medical sciences, agriculture, fishing, forestry, environmental, food-processing.
(Source: www.ausindustry.gov.au)
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited (ASX:CUV, XETRA/DAX:UR9, ADR:CUVLY) is an Australian
biopharmaceutical company developing its photo-protective drug CUV1647 as a preventative treatment for a
range of UV-related skin disorders as well as in cancer related treatments.
The five indications are:
Indication Description Clinical Trial Status
Polymorphic Light Eruption
(PLE / PMLE)
Sun poisoning Phase III trials began May 2007
Erythropoietic Protoporphyria (EPP) Absolute sun intolerance Phase III trials began June 2007
Squamous Cell Carcinoma (SCC)
and Actinic Keratosis (AK) in organ
transplant patients
Non-melanoma skin
cancers / precursor
to skin cancers
Phase II trials planned to
begin 2007
Solar Urticaria (SU) Acute anaphylactic
reaction to sun
Phase II trials planned to
begin 2007
Phototoxicity associated with
Photodynamic Therapy (PDT)
Photo-sensitivity associated
with cancer treatment
Phase II trials planned to
begin 2007
Phase I and II human clinical trials using CUV1647 have demonstrated that the drug is well tolerated and no
significant safety concerns have been identified to date.
Following successful conclusion of the development program, Clinuvel will work closely with global regulators to
facilitate marketing approval of CUV1647.
-END
Antwort auf Beitrag Nr.: 30.510.696 von spoon79 am 05.07.07 19:40:25du hast dich wohl verlaufen?
CUV letzter kurs in AUS 0,81 -2,41%
CUV letzter kurs in AUS 0,81 -2,41%
Was ist mit dem Kurs los? -23% gestern in Australien. Aus den News kann ich nichts schlechtes heraus lesen. Ihr vielleicht?
Antwort auf Beitrag Nr.: 30.491.039 von derneureiche am 04.07.07 21:18:16alles ok
gruss aus der verregneten hauptstadt

gruss aus der verregneten hauptstadt
Antwort auf Beitrag Nr.: 30.489.050 von ODI01 am 04.07.07 19:22:55tut mir leid wenn du dich auf dem schlips getreten fühlst, hast es warscheinlich gut gemeint.
aber das hat mit schlaumeierei nix zum tun. diese übesetzungen sind so grotten schlecht und geben of nicht den wirklichen sachverhalt wieder.
dann ist es besser auf ne gute übesetzte deutsche meldung zu warten, oder doch lieber seine englisch kenntnisse zu bemühen.
gruß aus dem verregneten süden
aber das hat mit schlaumeierei nix zum tun. diese übesetzungen sind so grotten schlecht und geben of nicht den wirklichen sachverhalt wieder.
dann ist es besser auf ne gute übesetzte deutsche meldung zu warten, oder doch lieber seine englisch kenntnisse zu bemühen.
gruß aus dem verregneten süden
29.01.25 · wO Chartvergleich · JAFCO Group |
25.06.24 · wO Chartvergleich · BAVARIA Industries Group Akt |
07.03.24 · EQS Group AG · Clinuvel Pharmaceuticals |